share_log

UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85

UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85

瑞銀維持對Apellis Pharmicals的買入,將目標股價下調至85美元
Benzinga ·  05/08 09:14

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to $85.

瑞銀分析師埃利安娜·梅爾維持Apellis Pharmicals(納斯達克股票代碼:APLS)的買入並將目標股價從89美元下調至85美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論